Skip to main content
SpringerLink
Log in

Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss

  • Chapter
  • First Online:
Bone-Metabolic Functions and Modulators

Part of the book series: Topics in Bone Biology ((TBB,volume 7))

  • 1060 Accesses

Abstract

The pharmacological management of postmenopausal osteoporosis (PMO) was heralded by the registration of injectable calcitonin, an antiresorptive agent that in the nasal formulation was shown to be effective to reduce the risk of incident vertebral fractures [14]. Other antiresorptive agents, with different mechanisms of action to inhibit bone resorption, then followed registration for management of PMO: estrogen, bisphosphonates, selective estrogen receptor modulators, and most recently, denosumab [6, 17, 20, 39, 40] Among these antiresorptive agents, the bisphosphonates became, and, to date, still are, the dominant pharmacological agent utilized to treat PMO [43, 47, 62, 66, 70]. Bisphosphonates this year celebrate their 40th anniversary since their introduction into clinical medicine [61].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baron R, Rawadi GA. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007;5(2):73–80.

    Article  PubMed  Google Scholar 

  2. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66.

    Article  PubMed  CAS  Google Scholar 

  3. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotogerin in postmenopausal women. J Bone Miner Res. 2001;16(2):348–60.

    Article  PubMed  CAS  Google Scholar 

  4. Bilezikian JP, Kurland ES. Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int. 2001;69(4):248–51.

    Article  PubMed  CAS  Google Scholar 

  5. Binkley N, Bone H, Eisman J, Hosking D et al (2010) Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: year 4 results. J Bone Miner Res; American Society of Bone and Mineral Research

    Google Scholar 

  6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41.

    Article  PubMed  CAS  Google Scholar 

  7. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–57.

    Article  PubMed  CAS  Google Scholar 

  8. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher CJ. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80.

    Article  PubMed  CAS  Google Scholar 

  9. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.

    PubMed  Google Scholar 

  10. Bonewald L. The amazing osteocyte. J Bone Miner Res. 2011;60:305–17.

    Google Scholar 

  11. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.

    Article  PubMed  CAS  Google Scholar 

  12. Brown JP, Prince RI, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61.

    Article  PubMed  CAS  Google Scholar 

  13. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.

    Article  PubMed  CAS  Google Scholar 

  14. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med. 2000;102:267–76.

    Article  Google Scholar 

  15. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011;49(1):71–5.

    Article  PubMed  CAS  Google Scholar 

  16. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1):151–8.

    Article  PubMed  CAS  Google Scholar 

  17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas PD, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, The FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

    Article  PubMed  CAS  Google Scholar 

  18. Egbuna OI, Cheung AM, Siddhanti S, Wang A, Daizadeh N, Anthony M, Grazette L, Miller PD (2010) Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification. Abstract book of the 43rd annual meeting of the American Society of Nephrology, Denver

    Google Scholar 

  19. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221–30.

    PubMed  CAS  Google Scholar 

  20. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebralfracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–45.

    Article  PubMed  CAS  Google Scholar 

  21. Fitzpatrick LA, Brennen E, Kumar S, et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res. 2008;23 Suppl 1:S50.

    Google Scholar 

  22. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Fuerst T, Engelke KA, Genant HK. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2011 Nov 2. doi:10.1002/jbmr.554

  23. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010;25(3):673–5.

    Article  PubMed  CAS  Google Scholar 

  24. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F. Generation and selection of novel fully human minoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285(51):40145–7.

    Article  Google Scholar 

  25. Greenspan SL, Bone HG, Macciott TB, et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1–84): results from the TOP study. J Bone Miner Res. 2005;20 Suppl 1:S56.

    Google Scholar 

  26. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert OpinTherTargets. 2009;13(4):485–96.

    CAS  Google Scholar 

  27. Horwitz MJ, Tedesco MB, Garcia-Ocana A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010;95(3):1279–87.

    Article  PubMed  CAS  Google Scholar 

  28. Hruska KA, Mathew S, Lund R, et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009;29(2):156–65.

    Article  PubMed  CAS  Google Scholar 

  29. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang Y, Egbuna OI, Boonen S, Miller PD. The effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–35.

    Article  PubMed  CAS  Google Scholar 

  30. Karsenty G, Gershon MD. The importance of the gastrointestinal tract in the control of bone mass accrual. Gastroenterology. 2011;141(2):439–42. Epub 2011 Jun 17.

    Article  PubMed  Google Scholar 

  31. Karsenty G, Oury F. The central regulation of bone mass. The first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab. 2010;95(11):4795–801.

    Article  PubMed  CAS  Google Scholar 

  32. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Ho-Shen M, Martin JA, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate. J Bone Miner Res. 2010;25:72–81.

    Article  PubMed  CAS  Google Scholar 

  33. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research ASBMR Task Force on Bisphosphonate-Associated ONJ. J Bone Miner Res. 2007;22(10):1479–91.

    Article  PubMed  Google Scholar 

  34. Kousteni S, Bilezikian JP. The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep. 2008;6(2):72–6.

    Article  PubMed  Google Scholar 

  35. Leung P, Pickarski M, Zhuo Y, Masarachia PJ. Duong LT (2011) The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011;49(4):623–35. Epub 2011 Jun 22.

    Article  PubMed  CAS  Google Scholar 

  36. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832–41.

    Article  PubMed  CAS  Google Scholar 

  37. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. Drugs. 2009;12(12):799–809.

    CAS  Google Scholar 

  38. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–88.

    Article  PubMed  CAS  Google Scholar 

  39. Lindsay R. The menopause and osteoporosis. Obstet Gynecol. 1996;87 Suppl 2:S16–9.

    Article  Google Scholar 

  40. Lindsay R. Hormones and bone health in postmenopausal women. Endocrine. 2004;24(3):223–30.

    Article  PubMed  CAS  Google Scholar 

  41. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.

    Article  PubMed  CAS  Google Scholar 

  42. McClung MR, Lewiecki EM, Bolognese M, Peacock M, Weimstein RL, Ding B, Geller ML, Grauer A, Wagman RB, Miller PD (2011) Effect of densoumab on bone mineral density and biochemical markers of bone turnover” results of an 8 year phase 2 clinical trial. J Clin Endocrinol Metab (in press)

    Google Scholar 

  43. Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):849–68.

    Article  PubMed  CAS  Google Scholar 

  44. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6:12–6.

    Article  PubMed  Google Scholar 

  45. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18–22.

    Article  PubMed  Google Scholar 

  46. Miller PD. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med. 2009;76:715–23.

    Article  PubMed  Google Scholar 

  47. Miller PD, Derman R. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int. 2010;21(11):1793–802. Epub 2010 Mar 23.

    Article  PubMed  CAS  Google Scholar 

  48. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.

    Article  PubMed  CAS  Google Scholar 

  49. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Martin JS, McClung MR. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96(2):1–6.

    Article  Google Scholar 

  50. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991–7.

    Article  PubMed  Google Scholar 

  51. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineraldensity in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.

    Article  PubMed  CAS  Google Scholar 

  52. O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3(8):e2942.

    Article  PubMed  Google Scholar 

  53. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25(10):2239–50.

    Article  PubMed  CAS  Google Scholar 

  54. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17.

    Article  PubMed  CAS  Google Scholar 

  55. Papapoulos S, Chapurlat R, Libanati C, Brandi M, Brown J, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski S, Reginster JY, Resch H, Román J, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley M, Grauer A, Cummings S, Bone H. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res. 2011 Nov 23. doi:10.1002/jbmr.1479.

  56. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (−/−) mice. Bone. 2009;44(2):199–207.

    Article  PubMed  CAS  Google Scholar 

  57. Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LB. Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Reports. 2011;9:72–6.

    Google Scholar 

  58. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816–22.

    Article  PubMed  CAS  Google Scholar 

  59. Reid IR, Hosking DJ. Bisphosphonates in Paget’s disease. Bone. 2011;49(1):89–94.

    Article  PubMed  CAS  Google Scholar 

  60. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter AI, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, Martin S, Ominsky MS, Dempster DW, on behalf of the Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the freedom and stand studies. J Bone Min Res. 2010;25:2256–65.

    Article  CAS  Google Scholar 

  61. Russell G, Burr D. 40th Anniversary of bisphosphonates. Bone. 2011;49(1):2–19.

    Article  PubMed  CAS  Google Scholar 

  62. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.

    Article  PubMed  CAS  Google Scholar 

  63. Saag KG, Shane E, Boonen S, et al. Teriparatide oralendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–39.

    Article  PubMed  CAS  Google Scholar 

  64. Shane E, Burr D, Ebeling P, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of The American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:1–28.

    Article  Google Scholar 

  65. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007;38(4):261–9.

    Article  PubMed  CAS  Google Scholar 

  66. Siris E, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction in US women aged 45 and older: 2001–2008. Bone. 2011;26:3–11.

    Google Scholar 

  67. Stopeck AT, Lipton A, Body J-J, et al. Densoumab compared with zoledronic acid for the treatment of bone metastisis in patients with advanced breast ­cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.

    Google Scholar 

  68. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–57.

    Article  PubMed  CAS  Google Scholar 

  69. Visentin L, Dodds RA, Valente M, et al. A selective inhibitor of the osteoclastic V-H(+)- ATPase prevents bone loss in both thyroparathyroidectomized and ovaricetomized rats. J Clin Invest. 2000;106:309–18.

    Article  PubMed  CAS  Google Scholar 

  70. Watts NB. Long term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–65.

    Article  PubMed  CAS  Google Scholar 

  71. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106–11.

    Article  PubMed  CAS  Google Scholar 

  72. Yadav VK, Ducy P. Lrp5 and bone formation: a serotonin-dependent pathway. Ann N Y Acad Sci. 2010;1192(1):103–9.

    Article  PubMed  CAS  Google Scholar 

  73. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16(3):308–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Colorado Center for Bone Research, Lakewood, CO, 80227, USA

    Paul D. Miller M.D., FACP

Authors
  1. Paul D. Miller M.D., FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul D. Miller M.D., FACP .

Editor information

Editors and Affiliations

  1. Health Center, Dept. Pharmacology, University of Connecticut, Farmington Ave. 263, Farmington, 06030-6125, Connecticut, USA

    Felix Bronner

  2. , Department of Biochemistry and Cell Biol, Rice University, 6100 Main Street, Houston, 77005, Texas, USA

    Mary C. Farach-Carson

  3. , General Hospital, University of Southampton, Southampton, SO16 6YD, United Kingdom

    Helmtrud I. Roach

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag London

About this chapter

Cite this chapter

Miller, P.D. (2012). Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss. In: Bronner, F., Farach-Carson, M., Roach, H. (eds) Bone-Metabolic Functions and Modulators. Topics in Bone Biology, vol 7. Springer, London. https://doi.org/10.1007/978-1-4471-2745-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2745-1_9

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2744-4

  • Online ISBN: 978-1-4471-2745-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation